Nehal Abd El-Ghaffar Heabah

Nehal Abd El-Ghaffar Heabah

Auto-generated profile, based on publicly available information

Nehal Abd El-Ghaffar Heabah

Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2021 in Journal of the Egyptian National Cancer Institute
Verified
Journal Article
Open access
PDF file
AEAsmaa Mustafa Eid
Asmaa Mustafa Eid
NHNehal Abd El-Ghaffar Heabah
Nehal Abd El-Ghaffar Heabah
Background: Medulloblastoma (MB) is a heterogeneous disease, displaying distinct genetic profiles with specific molecular subgroups. This study aimed to validate MB molecular subgrouping using surrogate immunohistochemistry and associate molecular subgroups, histopathological types, and available clinicopathological parameters with overall survival (OS) and progression-free survival (PFS) of MB patients. This study included 40 MBs; immunohistochemical staining, using β-catenin and GRB2-Associated Binding Protein 1 (GAB1) antibodies, was used to classify MB cases into wingless signaling activated (WNT), sonic hedgehog (SHH), and non-WNT/SHH molecular subgroups. Nuclear morphometric analysis (for assessment of degree of anaplasia) and Kaplan-Meier survival curves were done. Results: MB cases were classified into WNT (10%), SHH (30%), and non-WNT/SHH (60%) subgroups. Histopathological types differed significantly according to tumor location (p< 0.001), degree of anaplasia (p = 0.014), molecular subgroups (p < 0.001), and risk stratification (p = 0.008). Molecular subgroups differed significantly in age distribution (p = 0.031), tumor location (p< 0.001), histopathological variants (p < 0.001), and risk stratification (p < 0.001). OS was 77.5% and 50% after 1 and 2 years, while PFS was 65% and 27.5% after 1 and 2 years, respectively. OS and PFS were associated significantly with histopathological variants (p < 0.001 and 0.001), molecular subgroups (p = 0.012 and 0.005), and risk stratification (p < 0.001 and < 0.001), respectively. Conclusions: Medulloblastoma classification based on molecular subgroups, together with clinicopathological indicators, mainly histopathological types; accurately risk stratifies MB patients and predicts their survival.

20 July 2023 in Pathology - Research and Practice
Verified
Journal Article
Closed access
NHNehal Abd El-Ghaffar Heabah
Nehal Abd El-Ghaffar Heabah
SDSara A. Darwish
Sara A. Darwish
AEAsmaa Mustafa Eid
Asmaa Mustafa Eid

7 May 2024 in Parasite Immunology
Verified
Journal Article
Closed access
SYSalwa S. Younis
Salwa S. Younis
ASAmina M. Salama
Amina M. Salama
DEDalia A. Elmehy
Dalia A. Elmehy
NHNehal A. Heabah
Nehal A. Heabah
HRHanem M. Rabah
Hanem M. Rabah
GGGhada A. Gamea
Ghada A. Gamea

5 September 2020 in International Journal of Cancer and Biomedical Research
Verified
Journal Article
Closed access
NHNehal Abd El-Ghaffar Heabah
Nehal Abd El-Ghaffar Heabah
ABAsmaa Bedeer
Asmaa Bedeer
Background: Urinary bladder carcinoma is the most common urologic malignancy that includes phenotypically and genotypically diverse tumors. The development of new treatment modalities is essential to improve the outcomes and increase the overall survival of urinary bladder carcinoma patients’. Among these modalities, comes the PD-L1 inhibitors, as promising immunotherapy. P53 may also play a role in these treatment strategies. Aim: This study aimed to evaluate PD-L1 and p53 expression in urinary bladder carcinoma, and its available variants, and relate PD-L1 and p53 expression to each other and the available clinicopathological features. Materials and methods: This study included 60 cases of urinary bladder carcinoma, with no history of radiotherapy or chemotherapy, classified as follows: 32 cases of urothelial carcinoma, 25 squamous cell carcinomas, and 3 adenocarcinomas. Immunohistochemical staining of all cases using PD-L1 and p53 was done. Results: Positive PD-L1 expression was detected in 51.7% of all cases. PD-L1 expression was significantly associated with the histopathological types, high tumor grade and muscle invasion. High p53 expression was detected in 50% of the studied cases. P53 expression was significantly associated with high tumor grade, advanced stage, vascular invasion and lymph node metastasis. PD-L1 and p53 co-expression was detected in 33.3% of the cases. PD-L1 positivity was significantly associated with p53 expression. Conclusions: PD-L1 and p53 could be considered as predicting biomarkers for aggressive bladder carcinoma and their immunohistochemical expression may aid in identifying suitable patients for target therapy.

6 October 2020 in International Journal of Cancer and Biomedical Research
Verified
Journal Article
Closed access
NHNehal Abd El-Ghaffar Heabah
Nehal Abd El-Ghaffar Heabah
AEAsmaa Mustafa Eid
Asmaa Mustafa Eid
Introduction: Malignant mesothelioma (MM) is a lethal tumor of serosal surfaces. Its differentiation from reactive mesothelial hyperplasia is mandatory, and may be problematic in many situations. Thus, the application of a targeted panel of specific markers permits proper diagnosis in the majority of cases.Aim of the work: This study aimed to determine the potential use of BAP1 and CD147 antibodies to differentiate between MM and reactive mesothelial hyperplasia.Materials and methods: The current work was carried out on 120 cases (56 reactive mesothelial hyperplasia and 64 malignant mesothelioma cases), retrieved as 70 cell blocks and 50 tissue samples. Immunohistochemical staining, using calretinin (to confirm the mesothelial lineage), BAP1 and CD147 antibodies, was performed for each case. Results: Lost nuclear BAP1 expression was detected in 45.3% of the mesotheliomas versus 19.6% of reactive mesothelial hyperplasia cases. Positive membranous CD147 expression was found in 84.4% of mesothelioma cases versus 8.9% of reactive mesothelial hyperplasia cases. BAP1 showed 44.6% sensitivity and 80% specificity, while CD147 showed 84.3% sensitivity and 91% specificity in the diagnosis of malignant mesothelioma.Conclusions: Lost BAP1 expression and positive CD147 expression may be diagnostic of malignant mesothelioma and can exclude the diagnosis of reactive mesothelial proliferations; in both biopsy and cytology specimens. However, CD147 exhibits higher sensitivity and specificity than BAP1.

28 November 2023 in Journal of Immunoassay and Immunochemistry
Verified
Journal Article
Closed access
NHNehal Abd El-Ghaffar Heabah
Nehal Abd El-Ghaffar Heabah
SDSara A. Darwish
Sara A. Darwish
FIFatma Mkh Ibrahim
Fatma Mkh Ibrahim